Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand

Objective: This study aimed to investigate the clinical impact of HLA-B*15:02 pharmacogenomics (PGx) testing before carbamazepine (CBZ)/oxcarbazepine (OXC) prescriptions and to determine whether this PGx testing was associated with the reduction of CBZ/OXC-induced cutaneous adverse drug reactions (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiwattanon, Kanyawan, John, Shobana, Koomdee, Napatrupron, Jinda, Pimonpan, Rachanakul, Jiratha, Jantararoungtong, Thawinee, Nuntharadthanaphong, Nutthan, Kloypan, Chiraphat, Biswas, Mohitosh, Boongird, Apisit, Sukasem, Chonlaphat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294359/
https://www.ncbi.nlm.nih.gov/pubmed/35865943
http://dx.doi.org/10.3389/fphar.2022.867490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294359/
https://www.ncbi.nlm.nih.gov/pubmed/35865943
http://dx.doi.org/10.3389/fphar.2022.867490

Ejemplares similares